Live tape
Top 8, mentions 7d25,971NVDA12,906 mentions▲ +0.05ANT3,367 mentions▲ +0.07GOOGL2,569 mentions▲ +0.04SPCX1,755 mentions▲ +0.07SPY1,629 mentions▲ +0.05QQQ1,412 mentions▲ +0.05AMD1,248 mentions▲ +0.06AAPL1,085 mentions▲ +0.03

Equity · Healthcare

AKTX

NASDAQ

Akari Therapeutics (AKTX)

7.11 USD −0.84% vs prior close Nov 19, 2026
Akari Therapeutics, Plc price graph
61 sessions
12 6 24 Aug 19 Nov

The line runs 7.53 USD on 24 August through 7.11 USD on 19 November, on a scale from 6 to 12. Days the market did not trade hold the previous close, flat.

Market cap
1.32T USD
EPS, diluted, year to Dec 2025
0.00 USD
52-week range
3.06 USD – 22.21 USD
Avg volume
611.00

as of Nov 19, 2026

Have Akari Therapeutics (AKTX) insiders bought or sold shares recently?

In the 90 days to 21 Nov 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Form 4, 90 days to 21 Nov 2026, newest Form 4 filing 17 Nov 2026

0buys
0sells
10other filings
Have Akari Therapeutics (AKTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Nov 2026Farag Kameel D.Interim CFOAward2,87326K USD
14 Oct 2026Patel Sandip IDirectorOption exercise10,0524 USD
14 Oct 2026Bazemore Robert BDirectorOption exercise3,8662 USD
14 Oct 2026Gaslightwala AbizerCEOOption exercise27,06611 USD
05 Oct 2026Prudo-Chlebosz RaymondDirectorAward3,24026K USD
05 Oct 2026Huh HoyoungDirectorAward6,16049K USD
05 Oct 2026Patel Sandip IDirectorAward4,31334K USD
05 Oct 2026Bazemore Robert BDirectorAward4,67737K USD
05 Oct 2026Patel Samir RashmikantDirectorAward2,23618K USD
29 Sep 2026Gaslightwala AbizerCEOAward6,43062K USD

Which funds hold Akari Therapeutics (AKTX)?

1 of the 45 institutional funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2026 — a combined 201K USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Akari Therapeutics (AKTX)?
FundPositionSharesValueShares q/q
Citadel AdvisorsNew position21,637201K USD

What has been filed or recorded for Akari Therapeutics (AKTX)?

The filings we hold for Akari Therapeutics, newest first: 12 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Akari Therapeutics (AKTX)?
And
30 Oct 2026Fails to deliverShares failed to deliver3,419 shares29K USD notional · <0.001% of shares out
29 Oct 2026Fails to deliverShares failed to deliver3,238 shares30K USD notional · <0.001% of shares out
28 Oct 2026Fails to deliverShares failed to deliver2,931 shares25K USD notional · <0.001% of shares out
23 Oct 2026Fails to deliverShares failed to deliver24 shares198 USD notional · <0.001% of shares out
22 Oct 2026Fails to deliverShares failed to deliver1,624 shares14K USD notional · <0.001% of shares out
21 Oct 2026Fails to deliverShares failed to deliver2,295 shares21K USD notional · <0.001% of shares out
20 Oct 2026Fails to deliverShares failed to deliver167 shares2K USD notional · <0.001% of shares out
19 Oct 2026Fails to deliverShares failed to deliver1,197 shares10K USD notional · <0.001% of shares out
16 Oct 2026Fails to deliverShares failed to deliver3,846 shares33K USD notional · <0.001% of shares out
15 Oct 2026Fails to deliverShares failed to deliver2,582 shares19K USD notional · <0.001% of shares out
14 Oct 2026Fails to deliverShares failed to deliver1,394 shares11K USD notional · <0.001% of shares out
13 Oct 2026Fails to deliverShares failed to deliver4,909 shares42K USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS 0.00 USD
30 Sep 2026FinancialsTotal assets36.6M USDat period end
30 Sep 2026FinancialsTotal equity17.5M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 0.00 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS 0.00 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 0.00 USD
31 Dec 2025FinancialsNet income−17.3M USDfiscal year
31 Dec 2025FinancialsDiluted EPS0.00 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS 0.00 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.00 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.00 USD
31 Dec 2024Annual reportFY 2024 reportedEPS 0.00 USD

What do people ask about Akari Therapeutics (AKTX)?

From live data
What did Akari Therapeutics shares close at?7.11

Akari Therapeutics closed at 7.11 USD on 19 Nov 2026, down 0.84% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Akari Therapeutics’ market cap?1.32T

Akari Therapeutics is worth 1.32T USD by market value as of 19 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Akari Therapeutics insiders bought or sold shares recently?10 filings

In the 90 days to 21 Nov 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 10 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders

Which funds own Akari Therapeutics?1 of 45

1 of the 45 funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Citadel Advisors. See Funds

When did Akari Therapeutics last report earnings?0.00

Akari Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.00 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words